Argenx Se (ARGX) Receivables - Net (2015 - 2026)
Argenx Se's (ARGX) quarterly Receivables - Net came in at $1.9 billion in Q2 2026, down 99.84% YoY from $1197.1 billion in Q2 2025, and up 17.24% on a QoQ basis from $1.6 billion in Q4 2025.
Analysis
Argenx Se (ARGX) Receivables - Net (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Receivables - Net data on file, last reported at $1.9 billion in Q2 2026.
- Quarterly Receivables - Net fell 99.84% year-over-year to $1.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 billion (down 99.84% YoY) and the FY2025 annual result came in at $1.6 billion, up 82.1% from the prior year.
- Receivables - Net grew to $1.9 billion in Q2 2026, from $1.6 billion in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $1197.1 billion in Q2 2025 to a low of $112.4 million in Q2 2022.
- A 5-year average of $133.7 billion and a median of $652.9 million in 2024 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2025 — Receivables - Net soared 183253.63% — and 2026, when it slumped 99.84%.
- Tracing ARGX's Receivables - Net over 5 years: stood at $275.7 million in 2022, then soared by 80.16% to $496.7 million in 2023, then soared by 82.1% to $904.5 million in 2024, then surged by 82.1% to $1.6 billion in 2025, then advanced by 17.24% to $1.9 billion in 2026.
- The last three Receivables - Net figures came in at $1.9 billion (Q2 2026), $1.6 billion (Q4 2025), and $1197.1 billion (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.93 Bn |
| Dec 31, 2025 | 1.65 Bn |
| Jun 30, 2025 | 1,197.07 Bn |
| Dec 31, 2024 | 904.47 Mn |
| Jun 30, 2024 | 652.88 Mn |
| Dec 31, 2023 | 496.69 Mn |
| Jun 30, 2023 | 353.23 Mn |
| Dec 31, 2022 | 275.70 Mn |
| Jun 30, 2022 | 112.39 Mn |
| Dec 31, 2021 | 38.22 Mn |
| Jun 30, 2021 | 12.05 Mn |
| Dec 31, 2020 | 6.78 Mn |
| Jun 30, 2020 | 9.43 Mn |
| Dec 31, 2019 | 31.12 Mn |
| Jun 30, 2019 | 5.93 Mn |
| Dec 31, 2018 | 3.29 Mn |
| Jun 30, 2018 | 12.17 Mn |
| Dec 31, 2017 | 3.35 Mn |
| Jun 30, 2017 | 4.69 Mn |
| Dec 31, 2016 | 2.13 Mn |